GRAIL and Carrum Health Partner to Include Galleri® As Part of Comprehensive Cancer Care Offering to Employers
October 13, 2022
Through Carrum Health’s Network of Customers, Eligible Employees Will Have Access to GRAIL’s Galleri® Multi-Cancer Early Detection (MCED) Test
MCED Test Offered as Part of Comprehensive Value-Based Cancer Care to Improve Outcomes and Reduce Costs
MENLO PARK, Calif., and SAN FRANCISCO, Oct. 13, 2022 — GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Carrum Health, the first digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered, value-based care platform, today announced a first-of-its-kind partnership to include the Galleri® multi-cancer early detection (MCED) test as part of Carrum Health’s oncology offering to self-insured employers. This product integration will enable employers who offer Carrum Health benefits to provide eligible employees the Galleri test as part of the comprehensive cancer care Carrum delivers.
“In developing Carrum’s comprehensive oncology offering we’ve carefully selected partners who share in our mission to tackle both the rising costs of cancer care and solutions that vastly improve the patient experience,” said Sach Jain, CEO and founder of Carrum Health. “GRAIL’s early cancer detection test is a critical component in a comprehensive oncology offering and we’re thrilled to extend this benefit to Carrum members.”
In a clinical study, the Galleri test demonstrated the ability to detect a shared signal across more than 50 types of cancers, over 45 of which lack recommended screening tests today. Using advanced genomics and machine learning, the test also predicts the origin of the cancer signal, which enables targeted diagnostic evaluation. Recently announced results from the PATHFINDER clinical trial showed adding the Galleri MCED test to standard of care screening more than doubled the number of cancers detected, and the test predicted where a cancer signal originated with 97% accuracy.
“An MCED test like Galleri complements existing screenings and represents a new approach with the potential to find cancer at earlier stages and to improve healthcare outcomes and efficiencies,” said Bob Ragusa, chief executive officer at GRAIL. ”We are proud to partner with Carrum Health, who shares our commitment to transforming cancer care and reducing rising healthcare costs.”
Members who receive a signal detected from the Galleri test can work with a Carrum Health COE for diagnostic evaluation and guideline-concordant treatment planning. As part of Carrum Health’s comprehensive offering, members are paired with a personal patient care specialist who handles all administrative aspects of the program and guides the member throughout the entire journey. Once treatment starts with a selected provider, patients and their care team can leverage the COEs’ expertise for input and guidance as needed and will have access to an oncology-certified nurse and remote support services.
About Carrum Health
Carrum Health offers the first value-based complete surgical care platform that combines the benefits of a bundled payments Centers of Excellence (COE) with surgical guidance and coordination to deliver the highest quality, most appropriate care. By connecting self-insured employers with the top 10% of doctors and facilities across the nation, Carrum reduces unnecessary procedures by as much as 30% and aligns cost and care incentives to save employers up to 45% per episode of care, all validated by peer-reviewed publications. Carrum’s award-winning technology gives members access to a mobile app and Care Specialist that guides them through the surgery process, and a seamless platform integration to make COE adoption plug-and-play for employers. Backed by Tiger Global, Carrum was named to the 2021 CB Insights Digital Health 150 and named one of the best places to work in 2022 by Built In. The company, founded in 2014, is headquartered in Silicon Valley. For more information, visitcarrumhealth.com.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021.
The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect signals across more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test is available in the U.S. and requires a prescription from a licensed healthcare provider. The Galleri test should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.
All cells—cancer and healthy ones—shed DNA, which is called cell-free DNA, into the bloodstream. One of the “hallmarks of cancer” is when methyl groups are added to DNA. This does not alter the DNA code but it can alter gene expression. Methylation patterns on tumor-derived cell-free DNA carry cancer-specific signals and are therefore very helpful in detecting cancer and determining its origin. Galleri uses next-generation sequencing and machine learning algorithms to analyze these methylation patterns of cell-free DNA in the bloodstream.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.